ALDMS.PA Diagnostic Medical Systems SA
- Market cap
- EUR 23.6M
- P/E
- 45.5x
- P/B
- 1.20x
- ROE
- 8.1%
- Dividend yield
- -
- Fundamental score
- 1.3/5
Ratios use the latest price and the current fiscal year annualized from 1 quarter up to Jun 2026.
Is ALDMS.PA undervalued?
Graham numberALDMS.PA trades 55.9% above its Graham number.
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
Diagnostic Medical Systems SA fundamental analysis
3 of 11 checks passedROE 0/2
The stock's ROE indicates a negative return (-38.73%) on shareholders' equity, suggesting poor financial performance.
ROA 0/2
The stock's ROA (-14.41%) suggests that it's struggling to generate profits from its assets, making it a risky choice for investment.
PBV 2/2
The stock's low PBV ratio (0x) suggests it's undervalued, making it an attractive opportunity for investors.
DER 1/2
The stock maintains a fair debt to equity ratio (90%), indicating a reasonable balance between the money it owes and the ownership it possesses.
Revenue Growth 0/2
Company's revenue has remained stagnant over the past three years, indicating a lack of growth and making it a less favorable option.
Net Profit Growth 0/2
Despite the passage of five years, this company's net profit has not shown any improvement, highlighting a lack of growth and making it a less appealing investment prospect.
Assets Growth 2/2
This company's revenue has experienced steady growth over the last five years, indicating a reliable and prosperous financial trajectory.
Graham Number 0/1
The Graham number analysis indicates that this company's stock price is likely overpriced, raising concerns about its investment potential.
Dividend Growth 0/2
Potential investors should be aware that the company's dividend growth has shown no upward trend in the past three years, indicating limited potential for increased returns.
Dividend 0/2
The company has not distributed any dividends in the past three years, which may raise concerns for investors looking for regular income from their investments.
Buffet Intrinsic Value 0/1
The company's stock appears overvalued (0) by Warren Buffett's formula, suggesting a less favorable investment opportunity as its market price exceeds its estimated intrinsic value.
Each check is worth 1 or 2 points by how much it says about the quality of the company. The score is the share of points earned, out of 5. Ask AI to explain this score
Diagnostic Medical Systems SA stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About Diagnostic Medical Systems SA
Diagnostic Medical Systems S.A. designs, develops, manufactures, and sells medical imaging systems in France. The company offers ADAM, a software suite for imaging experts; R and F solutions, including Platinum Neo, Platinum Flex, and Optima; bone densitometers, including Stratos and Medix Series; MISTRAL, a manual chest and bone solution; and Camargue series which offers motorized radiographic systems to perform all types of bone and chest exams, including full spine and lo…
Full company profileDiagnostic Medical Systems SA financial statements
2026 annualized: Fiscal year 2026 is not finished. Income statement and cash flow are annualized from 1 quarter up to Jun 30, 2026, the balance sheet is the latest quarter. Figures change when the annual report is published.
Diagnostic Medical Systems SA annual financial statements
| Item | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 Anlz |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Income Statement | |||||||||||
| Revenue | 37.4M | 27.1M | 24.3M | 31.0M | 32.2M | 36.3M | 35.3M | 44.1M | 46.1M | 50.0M | 88.6M |
| Gross Profit | 16.8M | 9.81M | 6.70M | 8.60M | 12.6M | 13.9M | 13.8M | 16.0M | 18.4M | 1.67M | 5.33M |
| Operating Income | -1.59M | -3.64M | -5.19M | -4.44M | -3.37M | -834K | -5.88M | -2.27M | -346K | 1.85M | 4.79M |
| EBITDA | 304K | -2.47M | -3.80M | -979K | -182K | -364K | -2.95M | 875K | -527K | 4.21M | 8.84M |
| Net Income | -1.35M | -850K | -5.45M | -3.24M | -5.24M | -3.88M | -6.82M | -4.95M | -2.88M | -167K | 1.58M |
| EPS | -0.09 | -0.05 | -0.34 | -0.20 | -0.33 | -0.24 | -0.42 | -0.28 | -0.16 | -0.01 | 0.05 |
| Balance Sheet | |||||||||||
| Total Assets | 50.0M | 40.1M | 36.8M | 40.3M | 45.8M | 53.0M | 53.9M | 51.1M | 53.9M | 62.5M | 60.2M |
| Total Liabilities | 21.7M | 16.7M | 19.0M | 25.4M | 28.7M | 32.6M | 35.7M | 37.4M | 39.8M | 41.9M | 39.0M |
| Shareholders' Equity | 24.8M | 23.5M | 18.1M | 14.7M | 17.0M | 18.7M | 15.7M | 12.4M | 12.8M | 19.1M | 19.6M |
| Cash & Short-term Investments | 8.14M | 4.12M | 1.05M | 1.48M | 1.70M | 4.20M | 4.39M | 5.72M | 6.05M | 8.07M | 4.56M |
| Total Debt | 6.21M | 5.76M | 6.62M | 9.82M | 14.8M | 15.9M | 15.4M | 20.1M | 20.1M | 18.7M | 19.3M |
| Cash Flow | |||||||||||
| Operating Cash Flow | -802K | -3.56M | -730K | 364K | -3.69M | -1.08M | 960K | -1.65M | 3.60M | -254K | -10.0M |
| Capital Expenditure | 3.32M | 3.72M | 3.24M | 3.38M | 3.08M | 5.88M | 2.60M | 2.72M | 3.57M | 2.92M | 5.17M |
| Free Cash Flow | -4.12M | -7.28M | -3.97M | -3.01M | -6.77M | -6.96M | -1.64M | -4.37M | 30.0K | -3.17M | -15.2M |
| Ratios | |||||||||||
| ROE | -5.4% | -3.6% | -30.2% | -22.1% | -30.8% | -20.7% | -43.5% | -39.9% | -22.4% | -0.9% | 8.1% |
| ROA | -2.7% | -2.1% | -14.8% | -8.0% | -11.4% | -7.3% | -12.7% | -9.7% | -5.3% | -0.3% | 2.6% |
| Net Profit Margin | -3.6% | -3.1% | -22.4% | -10.4% | -16.3% | -10.7% | -19.3% | -11.2% | -6.3% | -0.3% | 1.8% |
| Debt to Equity | 0.25x | 0.25x | 0.37x | 0.67x | 0.87x | 0.85x | 0.98x | 1.62x | 1.56x | 0.98x | 0.98x |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Total Debt
- Short and long-term borrowings.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
- Debt to Equity
- Total debt divided by shareholders' equity.
Diagnostic Medical Systems SA dividends
Diagnostic Medical Systems SA has not paid dividends in the last 9 fiscal years.
Last stock split: 1:10 on Jul 21, 2016.
Who owns Diagnostic Medical Systems SA
- Insiders 30.01%
- Institutions 15.45%
- Public & others 54.54%
- Shares outstanding 25.9M
- Free float 13.7M
Diagnostic Medical Systems SA company profile
- Company name
- Diagnostic Medical Systems SA
- Ticker
- ALDMS.PA
- ISIN
- FR0012202497
- Exchange
- Euronext Paris
- Sector
- Healthcare
- Industry
- Health Care Equipment & Supplies
- Employees
- 136
- Fiscal year end
- December
- Address
- 9 Avenue du Canal Philippe Lamour, Gallargues-le-Montueux, France, 30 660
- Phone
- 33 4 66 29 09 07
- Website
- dms-imaging.com
About Diagnostic Medical Systems SA
Diagnostic Medical Systems S.A. designs, develops, manufactures, and sells medical imaging systems in France. The company offers ADAM, a software suite for imaging experts; R and F solutions, including Platinum Neo, Platinum Flex, and Optima; bone densitometers, including Stratos and Medix Series; MISTRAL, a manual chest and bone solution; and Camargue series which offers motorized radiographic systems to perform all types of bone and chest exams, including full spine and long leg exams. It also provides mobiles under the !M1, ONYX, Rafale/Rafale DR, and !Mobile Wall Stand names; c-arm products under the EVO R+ FP ADAM and EVO + / EVO R+ names; retrofit kits; and mammography equipment. The company was founded in 1979 and is headquartered in Gallargues-le-Montueux, France.
Diagnostic Medical Systems SA management
5- Mr. Samuel SancerniChairman & CEO
- Ms. Valerie PugnaloniDirector of Administrative & Financial
- Mr. Jerome DelanoeDirector of Operations
- Swan TufferyDirector of Research and Development & Compliance
- Ms. Nathalie Caire RichardHuman Resources Director